Jie (Jay) Cheng, MD, PhD

Dr. Jie Cheng earned his medical degree from Shanghai Medical University in Shanghai City, Shanghai, China. He received residency training in internal medicine and received a Ph.D. in biomedical engineering at Case Western Reserve University in Cleveland, Ohio. Dr. Cheng’s fellowship in cardiology was completed at the University of Chicago in Illinois and his fellowship in electrophysiology was completed at the University of California in San Francisco. He is board-certified in electrophysiology and cardiology and specializes in cardiovascular disease and cardiac electrophysiology.

See Publications

Texas Heart Institute Positions

  • Director, Electrophysiology Basic Research
  • Teaching Staff, Cardiovascular Disease Fellowship
  • Teaching Staff, Clinical Cardiac Electrophysiology Fellowship

Interests

  • Cardiology
  • Electrophysiology

Education

  • Medical School:

    Shanghai Jiao Tong University School of Medicine

  • Residency:

    Mount Sinai Medical Center

  • Fellowships:

    University of Chicago

Academic & Clinical Affiliations

  • Baylor St. Luke's Medical Center
  • Memorial Hermann

Honors, Awards and Memberships

Publications

Zhang, Y., Sun, C., Li, Y. et al. (2022). Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14, eabo1981. https://doi.org/10.1126/scitranslmed.abo1981.
Li, K., Segura, A. M., Sun, J. et al. (2022). Rare delayed cardiac tamponade in a pig after cardiac surgery. Vet Med Sci. https://doi.org/10.1002/vms3.892.
Chen, Q., Pollet, M., Mehta, A. et al. (2021). Delayed removal of a percutaneous left ventricular assist device for patients undergoing catheter ablation of ventricular tachycardia is associated with increased 90-day mortality. J Interv Card Electrophysiol 62, 49–56. https://doi.org/10.1007/s10840-020-00875-y.
Zhang, Y., Li, Y., Hu, Q. et al. (2020). The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol 22, 1332–1345. https://doi.org/10.1038/s41556-020-00595-5.
Ma, Y., Cheng, N., Sun, J. et al. (2020). Atherogenic L5 LDL induces cardiomyocyte apoptosis and inhibits KATP channels through CaMKII activation. Lipids Health Dis 19, 189. https://doi.org/10.1186/s12944-020-01368-7.
Parikh, V., Rasekh, A., Mohanty, S. et al. (2020). Exclusion of electrical and mechanical function of the left atrial appendage in patients with persistent atrial fibrillation: differences in efficacy and safety between endocardial ablation vs epicardial LARIAT ligation (the EXCLUDE LAA study). J Interv Card Electrophysiol 57, 409–416. https://doi.org/10.1007/s10840-019-00657-1.
Long, S., Xi, Y., Gao, L. et al. (2020). Safety and efficacy of catheter ablation in atrial fibrillation patients with left ventricular dysfunction. Clin Cardiol 43, 305–314. https://doi.org/10.1002/clc.23314.
Zhao, Z., Liu, X., Gao, L. et al. (2020). Benefit of contact force-guided catheter ablation for treating premature ventricular contractions. Tex Heart Inst J 47, 3–9. https://doi.org/10.14503/THIJ-17-6441.
Parikh, V., Bartus, K., Litwinowicz, R. et al. (2019). Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device. J Cardiovasc Electrophysiol 30, 2849–2857. https://doi.org/10.1111/jce.14229.
Sharma, S. P., Turagam, M. K., Gopinathannair, R. et al. (2019). Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol 74, 2267–2274. https://doi.org/10.1016/j.jacc.2019.08.1045.